Navigation Links
What relates to the short-term effectiveness of biliary drainage?
Date:11/18/2009

Biliary drainage is performed as a palliative treatment of hilar cholangiocarcinoma. The reduction of serum bilirubin is usually the hallmark of successful biliary drainage. However, some patients may have persistent jaundice or scanty bile output after biliary drainage.

A research team, led by Dr. Chiung-Yu Chen from National Cheng Kung University retrospectively analyzed the clinical and imaging characteristics of these patients in an attempt to identify the factors related to bile output and reduction of serum bilirubin after percutaneous transhepatic biliary drainage (PTBD).

Their was published on November 7, 2009 in the World Journal of Gastroenterology.

The results showed patients with more bile duct visualized on percutaneous transhepatic cholangiography or absence of multiple liver metastases on imaging studies had more bile output after biliary drainage [odds ratio (OR): 8.471, P = 0.010 and OR: 1.959, P = 0.022, respectively]. Patients with prolonged prothrombin time had a slow decrease in serum bilirubin (OR: 0.437, P = 0.005). The median survival time was not significantly different in patients with low or high bile output (75 d vs 125 d, P = 0.573) or in patients with slow or rapid reduction of serum bilirubin (88 d vs 94 d, P = 0.576).

The authors suggested the effectiveness of percutaneous biliary drainage can be properly estimated before the procedure. Patient should be observed for daily bile output as well as the reduction of serum bilirubin. An initially well functioning biliary drainage does not link to a longer survival of patients and further efforts to maintain biliary patency are required.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Cancer patients quality of life directly relates to their survival
2. Employee cardiovascular health relates to psychological well-being
3. Pilot study relates phthalate exposure to less-masculine play by boys
4. Physiotherapy has short-term benefits for patients after knee surgery
5. Short-term hemofiltration is cost-effective for severe acute pancreatitis
6. The Westaim Corporation update on status of short-term investments
7. Journal Sleep: A short-term dose of zolpidem is an effective treatment for insomnia
8. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
9. Short-term use of antipsychotics in older adults with dementia linked to serious adverse events
10. New data show patients using avonex reported less sick leave and short-term disability costs
11. Assessing the real risk of heart disease in young people with low short-term risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into its VIP Woman of the ... for leadership in business. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Job satisfaction is essential ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Linda Cade as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to recognize Linda with this important honor,” said NAPW ...
(Date:6/1/2015)... June 01, 2015 Carson Energy also ... their investors IRA transactions. AdvantaIRA Trust, LLC is the ... the ability to fund positions using IRA’s does 2 ... on a project, even if there current cash position ... additional funding source for Carson and their investors to ...
(Date:6/1/2015)... The Delta Dental Foundation is currently seeking ... Michigan, Ohio and Indiana for its Brighter Futures Community ... has been set. , Across the tri-state area, the ... specifically focus on children’s oral health and $100,000 in ... adults. Each grant request will be considered and carefully ...
(Date:6/1/2015)... 01, 2015 EBSCO Health , ... introduced DynaMed Plus™ , a cross-platform evidence-based clinical ... It provides clinicians with the ideal blend of evidence ... paths. , DynaMed Plus is a significant enhancement ... the most frequently updated evidence-based content. DynaMed Plus content ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Linda Cade, Senior Product Manager at Sage, Into its VIP Professional Woman of the Year Circle 2Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Brighter Futures Community Grants Program Seeks to Help Fund Local Oral Health Programs 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 2Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 3Health News:EBSCO Health’s New DynaMed Plus™ Delivers Trusted, Evidence-Based Content to Physicians on Any Platform 4
... University of California, San Diego, have identified a key ... in humans and mice. This groundbreaking discovery has implications ... of patients with pulmonary arterial hypertension and prevent the ... this debilitating disease. In a paper to be ...
... today,s Scientific Program of the 2009 American Academy of ... Meeting include: John T. Flynn, MD, Columbia University School ... in caring for the vision of the tiniest premature ... Stanford University School of Medicine, on barriers to glaucoma ...
... ... Advantage has developed a proprietary web application named “iCompli®” designed to ... their physician protocols. The application is designed to notify the ... their mobile phone. iCompli® will work with any mobile device or ...
... patients have best chance at some visual recovery, research suggests ... improve the vision of people with a severe form of ... new study shows. , People with LCA, which is caused ... vision loss and abnormal eye movements in early infancy and ...
... ... Debate , ... (Vocus) October 22, 2009 -- According to the Centers for Disease Control and Prevention, the ... country. They also report that hospitalizations of related cases have been above average for this ...
... "Physician ... of EMR Adoption , , ... Doylestown, PA (PRWEB) October 23, 2009 -- myemrchoice.com announced that they will ... Doctors EMR Quarterly and the EMR Power Ranking. The new EMR planning resources ...
Cached Medicine News:Health News:UC San Diego researchers reverse pulmonary arterial hypertension in mouse models 2Health News:Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic 2Health News:Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic 3Health News:Bariatric Advantage Launches First of Its Kind Mobile Vitamin Reminder Web Application 2Health News:Gene Therapy Offers Hope for Severe Hereditary Eye Disease 2Health News:Progressive Radio Network Takes on Controversial H1N1 Vaccine Debate 2Health News:Progressive Radio Network Takes on Controversial H1N1 Vaccine Debate 3Health News:MyEMRchoice.com develops EMR Power Rankings for Selection of Electronic Medical Records 2
(Date:6/2/2015)... June 2, 2015 ... mejora  de 7,9 meses en la supervivencia libre ... con cáncer colorrectal metastático inoperable (mCRC) tratados  en ... Y-90 más quimioterapia    Los beneficios ... directamente al hígado con la quimioterapia sistémica actual ...
(Date:6/1/2015)... June 2, 2015 Amgen (NASDAQ: ... on a Phase 1b study to evaluate the ... oncolytic immunotherapy, in combination with Roche,s investigational anti-PDL1 ... with triple-negative breast cancer and colorectal cancer with ... investigational oncolytic immunotherapy designed to selectively replicate in ...
(Date:6/1/2015)... , June 1, 2015   Regulus Therapeutics ... company leading the discovery and development of innovative ... G. Xanthopoulos , Ph.D. has resigned as President ... of Regulus, Board of Directors, effective today, to ... Grint, M.D., who previously served as Chief Medical ...
Breaking Medicine Technology:Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 3Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 4Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 5Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 6Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 7Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 8Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 2Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 3Regulus' Kleanthis G. Xanthopoulos, Ph.D., to Step Down as President and Chief Executive Officer 4
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
... a basic Peripheral Nerve Locator only, which ... location during regional anesthesia. Ideal for day ... constant current NS232, NS252, NS272 PNS are ... programmed. ,Hand-held, battery operated, and includes automatically ...
Pocket-size digital nerve locator optimizes ease and convenience of performing peripheral nerve blocks. Includes RBW-5L electrode lead set, 9V alkaline battery, and durable molded polyethylene carryi...
Single cuff electronic tourniquet....
The Lone Star Retractor System may be adapted to a specific region of the anatomy by simply adjusting the hinges. The system also includes multiple ring shapes, slots on perifephery of retractor ring...
Medicine Products: